Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | HBB | P68871 | 1/20 | 0.64 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.40 |
| ▸ | TK2 | O00142 | 2/20 | 0.37 |
| ▸ | TK1 | P04183 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | PYGM | P11217 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178042 | 1.00 | LMNA (0.64) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL21178114 | 0.92 | LMNA (0.64) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL16328130 | 0.86 | SMN1; SMN2 (0.65) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL21179248 | 0.79 | LMNA (0.38) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL15060572 | 0.79 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL14564897 | 0.79 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL8094 | 0.79 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL98005 | 0.79 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL8095 | 0.79 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL14291576 | 0.79 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399227-A1 | 5-FLUOROURACIL COMPOUNDS | NUCORION PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399227-A1 | 5-FLUOROURACIL COMPOUNDS | DPYD, DHFR, FAU | LMNA 1225/4885SMN1; SMN2 1144/4885MAPT 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.